Moderna Inc (NASDAQ:MRNA) shares are trading higher by 3.8% at $457.32 amid strength in vaccine names. FDA authorization of a booster shot from competitors BioNTech and Pfizer has possibly lifted sector sentiment as well.
Peer vaccine producer, Novavax (NASDAQ:NVAX), is also trading higher after the company, along with Serum Institute, announced submission to the World Health Organization for emergency use listing for Novavax’s COVID-19 vaccine candidate.
Moderna is commercial-stage biotech that was founded in 2010. The firm’s mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease and rare genetic diseases.
Moderna has a 52-week high of $497.49 and a 52-week low of $63.64.
